DE69332732D1 - Pharmazeutische Zusammensetzung und Methode zur Behandlung von Hyperlipidämie und Arterioskerose - Google Patents

Pharmazeutische Zusammensetzung und Methode zur Behandlung von Hyperlipidämie und Arterioskerose

Info

Publication number
DE69332732D1
DE69332732D1 DE69332732T DE69332732T DE69332732D1 DE 69332732 D1 DE69332732 D1 DE 69332732D1 DE 69332732 T DE69332732 T DE 69332732T DE 69332732 T DE69332732 T DE 69332732T DE 69332732 D1 DE69332732 D1 DE 69332732D1
Authority
DE
Germany
Prior art keywords
hyperlipidemia
arteriosclerosis
treatment
pharmaceutical composition
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69332732T
Other languages
English (en)
Other versions
DE69332732T2 (de
Inventor
Kazuhiro Aikawa
Kozo Aoki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujifilm Corp
Original Assignee
Fuji Photo Film Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP4204122A external-priority patent/JP2907646B2/ja
Priority claimed from JP23476792A external-priority patent/JPH0680563A/ja
Application filed by Fuji Photo Film Co Ltd filed Critical Fuji Photo Film Co Ltd
Application granted granted Critical
Publication of DE69332732D1 publication Critical patent/DE69332732D1/de
Publication of DE69332732T2 publication Critical patent/DE69332732T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
DE69332732T 1992-07-30 1993-07-29 Pharmazeutische Zusammensetzung und Methode zur Behandlung von Hyperlipidämie und Arterioskerose Expired - Fee Related DE69332732T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP4204122A JP2907646B2 (ja) 1992-07-30 1992-07-30 抗高脂血症剤及び抗動脈硬化症剤
JP23476792A JPH0680563A (ja) 1992-09-02 1992-09-02 抗高脂血症剤及び抗動脈硬化症剤

Publications (2)

Publication Number Publication Date
DE69332732D1 true DE69332732D1 (de) 2003-04-10
DE69332732T2 DE69332732T2 (de) 2003-11-13

Family

ID=26514294

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69332732T Expired - Fee Related DE69332732T2 (de) 1992-07-30 1993-07-29 Pharmazeutische Zusammensetzung und Methode zur Behandlung von Hyperlipidämie und Arterioskerose

Country Status (3)

Country Link
US (1) US5387600A (de)
EP (1) EP0583665B1 (de)
DE (1) DE69332732T2 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995021160A1 (fr) * 1994-02-04 1995-08-10 Fuji Photo Film Co., Ltd. Derive de 2-mercaptobenzimidazole et agent antihyperlipemique et antiarteriosclerotique le contenant
JPH10504525A (ja) * 1994-05-27 1998-05-06 ジェイムズ・ブラック・ファウンデーション・リミテッド ガストリンとｃｃｋ拮抗薬
JP3559045B2 (ja) * 1994-06-10 2004-08-25 ナウチノ−イススレドバテルスキ インスティテュト ファルマコロギイ ロスシイスコイ アカデミイ メディツィンスキフ ナウク 薬理学的活性を有する２−メルカプトベンズイミダゾール誘導体
US6028103A (en) * 1994-09-16 2000-02-22 Children's Medical Center Corporation Triaryl methane compounds and analogues thereof useful for the treatment or prevention of sickle cell disease or diseases characterized by abnormal cell proliferation
US6562854B2 (en) * 1994-12-14 2003-05-13 Axys Pharmaceuticals, Inc. Compositions comprising a substituted benzimidazole useful for treating immunomediated inflammatory disorders
US6444694B1 (en) 1995-06-06 2002-09-03 Wyeth Styryl benzimidazole derivatives
US6288100B1 (en) 1995-06-06 2001-09-11 American Home Products Corporation Benzimidazole derivatives
US5880146A (en) * 1995-06-07 1999-03-09 Fuji Immunopharmaceuticals Corporation Inhibition of IL-12-induced IFN-γ synthesis by specific bis-phenol compounds as a method of immune modulation
US5654436A (en) * 1995-06-07 1997-08-05 American Home Products Corporation 2-substituted benzimidazole derivatives
US5684030A (en) * 1995-06-07 1997-11-04 American Home Products Corporation 2-substituted benzimidazole derivatives
WO1997003970A1 (en) 1995-07-17 1997-02-06 Fuji Photo Film Co., Ltd. Benzimidazole compounds
JP4376970B2 (ja) 1996-03-20 2009-12-02 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 鎌状赤血球症のためのトリアリールメタン化合物
US5889038A (en) 1996-03-20 1999-03-30 Children's Hospital Methods and products for treating diarrhea and scours: use of clotrimazole and related aromatic compounds
US5763473A (en) * 1996-12-06 1998-06-09 American Home Procucts Corporation Use of 2-substituted benzimidazole as smooth muscle cell proliferation inhibitors
AU749960B2 (en) 1997-11-20 2002-07-04 Children's Medical Center Corporation Substituted 11-phenyl-dibenzazepine compounds useful for the treatment or prevention of diseases characterized by abnormal cell proliferation
US6992079B2 (en) 1997-11-20 2006-01-31 President Fellows of Harvard College Substituted 11-phenyl-dibenzazepine compounds useful for the treatment or prevention of diseases characterized by abnormal cell proliferation
US6800658B2 (en) 1997-11-20 2004-10-05 Children's Medical Center Corporation Substituted diphenyl indanone, indane and indole compounds and analogues thereof useful for the treatment of prevention of diseases characterized by abnormal cell proliferation
US20040072862A1 (en) * 1999-06-04 2004-04-15 Bitler Catherine M. Compositions for treating ischemia-related neuronal damage
WO2000075117A1 (en) 1999-06-04 2000-12-14 Elan Pharma International Ltd. Compositions and methods for inhibiting cell death
WO2001000588A1 (fr) 1999-06-28 2001-01-04 Fuji Photo Film Co., Ltd. Composes de benzimidazole et medicaments les contenant
KR20020025091A (ko) 1999-06-30 2002-04-03 무네유키 가코우 벤즈 이미다졸 화합물 및 그것을 함유하는 의약
JP4624616B2 (ja) 1999-07-07 2011-02-02 富士フイルム株式会社 ベンズイミダゾール化合物
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
FR2842423B1 (fr) * 2002-07-18 2005-07-08 Centre Nat Rech Scient Composes a activite anti-parasitaire et medicaments les renfermant
JP2004115397A (ja) * 2002-09-25 2004-04-15 Fuji Photo Film Co Ltd 血管疾患治療薬を含むリポソーム
SE0302573D0 (sv) 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
EP1718608B1 (de) 2004-02-20 2013-07-17 Boehringer Ingelheim International GmbH Virale polymerasehemmer
RU2374234C2 (ru) 2004-09-24 2009-11-27 Астразенека Аб Бензимидазольные производные, содержащие их композиции, их получение и применение
GB0510585D0 (en) * 2005-05-24 2005-06-29 Novartis Ag Organic compounds
ES2402305T3 (es) 2006-01-24 2013-04-30 Janssen Pharmaceutica N.V. Benzimidazolas 2-sustituidas nuevas como moduladores del receptor de andrógeno selectivo (SARMS)
TW200745049A (en) 2006-03-23 2007-12-16 Astrazeneca Ab New crystalline forms
TW200808769A (en) 2006-04-18 2008-02-16 Astrazeneca Ab Therapeutic compounds
EP2341924A4 (de) 2008-10-02 2013-01-23 David Gladstone Inst Verfahren zur behandlung von hepatitis-c-virusinfektionen
CN110407801B (zh) * 2019-08-13 2020-12-22 陕西中医药大学 3,4-亚甲二氧基苯氧基贝特酸-(3,4-亚甲二氧基)苯酯类化合物及其降血脂应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1209558A (en) * 1968-07-06 1970-10-21 Delalande Sa Derivatives of 5-cinnamoyl benzofuran and process for their preparation
ZA825106B (en) * 1981-08-13 1983-04-27 Haessle Ab Novel pharmaceutical compositions
GB8417171D0 (en) * 1984-07-05 1984-08-08 Beecham Group Plc Compounds
HU193951B (en) * 1985-03-11 1987-12-28 Richter Gedeon Vegyeszet Process for producing new sulfur-containing 5-substituted benzimidazol derivatives and pharmaceutical compositions containing them
IT1226726B (it) * 1988-07-29 1991-02-05 Zambon Spa Composti attivi come inibitori della biosintesi del colesterolo.

Also Published As

Publication number Publication date
DE69332732T2 (de) 2003-11-13
EP0583665A3 (en) 1994-05-18
EP0583665B1 (de) 2003-03-05
US5387600A (en) 1995-02-07
EP0583665A2 (de) 1994-02-23

Similar Documents

Publication Publication Date Title
DE69332732D1 (de) Pharmazeutische Zusammensetzung und Methode zur Behandlung von Hyperlipidämie und Arterioskerose
BR9407799A (pt) Composição de matéria método de tratamento e composição farmaceutica
DE69622074D1 (de) Cystin-Silikon-Copolymere und deren Verwendung zur Behandlung von keratinischen Materialien
DE69836752D1 (de) Prostaglandinagoniste und deren verwendung zur behandlung von knochenerkrankungen
DE69631157D1 (de) Pharmazeutische Zubereitung zur Verwendung in der Behandlung von Diabetes
UA26213C2 (uk) Засіб для профілактики та лікуваhhя остеопорозу та фармацевтичhа композиція hа їх осhові
DE69117117T2 (de) Reinigungszusammensetzung zur Vorbeugung und Milderung von Hautreizungen
DE4497905T1 (de) Pharmazeutische Zusammensetzung zur Prävention und Behandlung des Motion-Sickness-Syndroms
DE69331265T2 (de) Verbindungen zur behandlung von entzündlichen erkrankungen und zur hemmung der produktion von tumornekrosefaktor
EE9800234A (et) Ravimeetod ja farmatseutiline kompositsioon
ATE227127T1 (de) Hochdosiertes chromtripicolinat zur behandlung von typ-ii-diabetes
DE19580261D2 (de) Pharmazeutische Zubereitungen und Arzneistoffe zur Prävention und Behandlung endothelialer Dysfunktion
DE69532066D1 (de) Arzneimittel zur Behandlung von Restenosis und Gefässsklerose
DE69734296D1 (de) Neue dikaffeoylchinasäurederivate und deren verwendung zur behandlung von hepatitis b
DE69620691T2 (de) Therapeutisches Mittel zur Behandlung der Hypercholesterinämie
DE69426848T2 (de) Gerät zur Behandlung von lichtempfindlichen Materialien
DE69420229T2 (de) Pharmazeutische Zusammensetzung zur Behandlung von AIDS
DE69825319D1 (de) Präparat zur vorbeugung und behandlung von entzündungen
DE69625883D1 (de) Zusammensetzung zur Reinigung und/oder Desinfektion von medizinischen Geräten
DE69325141D1 (de) Behandlung von lignozellulosehaltigen Materialien
DE69418931T2 (de) Verwendung von VIP und deren Analogen und Fragmenten zur Behandlung von neurodegenerativen Krankheiten
DE69726071D1 (de) Pharmazeutische Zusammensetzung zur Verhütung und/oder Behandlung von Krankheiten mit Bezug auf Apoptose
DE69412178T2 (de) Apparat zur Behandlung von Lagen
DE59309732D1 (de) Arzneimittel zur behandlung und prophylaxe von knochen- und gelenkserkrankungen
ATE224711T1 (de) Formulierung zur behandlung und/oder vorbeugung von dementia

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: FUJIFILM CORP., TOKIO/TOKYO, JP

8339 Ceased/non-payment of the annual fee